Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Daniel Weintraub; Tanya Simuni; Chelsea Caspell-Garcia; Christopher Coffey; Shirley Lasch; Andrew Siderowf; Dag Aarsland; Paolo Barone; David Burn; Lama M. Chahine; Jamie Eberling; Alberto J. Espay; Eric D. Foster; James B. Leverenz; Irene Litvan; Irene Richard; Matthew D. Troyer; Keith A. Hawkins; Kenneth Marek; Danna Jennings; Caroline Tanner; Karl Kieburtz; Werner Poewe; Brit Mollenhauer; Tatiana Foroud; Douglas Galasko; Todd Sherer; Sohini Chowdhury; Mark Frasier; Catherine Kopil; Vanessa Arnedo; Alice Rudolph; John Seibyl; Susan Mendick; Norbert Schuff; Chelsea Caspell; Liz Uribe; Eric Foster; Katherine Gloer; Jon Yankey; Arthur Toga; Dorit Berlin; Paola Casalin; Giulia Malferrari; John Trojanowski; Les Shaw; David Russell; Stewart Factor; Penelope Hogarth; David Standaert; Robert Hauser; Joseph Jankovic; Matthew Stern; Lama Chahine; Samuel Frank; Klaus Seppi; Holly Shill; Daniela Berg; Zoltan Mari; Nicola Pavese; Alberto Espay; Johnna Devoto; Dominic Rowe; Melanie Brandabur; Roy Alcalay; Eduardo Tolosa; Michele York; Laura Leary; Cheryl Riordan; Linda Rees; Alicia Portillo; Art Lenahan; Karen Williams; Stephanie Guthrie; Ashlee Rawlins; Sherry Harlan; Christine Hunter; Baochan Tran; Cathi Ann Thomas; Raymond James; Fabienne Sprenger; Diana Willeke; Sanja Obradov; Jennifer Mule; Katharina Gauss; Deborah Fontaine; Bina Shah; Madelaine Ranola; John R. Sims; Parkinson's Progression Markers Initiative

doi:10.1002/mds.26170

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Daniel Weintraub^*, Tanya Simuni, Chelsea Caspell-Garcia, Christopher Coffey, Shirley Lasch, Andrew Siderowf, Dag Aarsland, Paolo Barone, David Burn, Lama M. Chahine, Jamie Eberling, Alberto J. Espay, Eric D. Foster, James B. Leverenz, Irene Litvan, Irene Richard, Matthew D. Troyer, Keith A. Hawkins, Kenneth Marek, Danna JenningsCaroline Tanner, Karl Kieburtz, Werner Poewe, Brit Mollenhauer, Tatiana Foroud, Douglas Galasko, Todd Sherer, Sohini Chowdhury, Mark Frasier, Catherine Kopil, Vanessa Arnedo, Alice Rudolph, John Seibyl, Susan Mendick, Norbert Schuff, Chelsea Caspell, Liz Uribe, Eric Foster, Katherine Gloer, Jon Yankey, Arthur Toga, Dorit Berlin, Paola Casalin, Giulia Malferrari, John Trojanowski, Les Shaw, David Russell, Stewart Factor, Penelope Hogarth, David Standaert, Robert Hauser, Joseph Jankovic, Matthew Stern, Lama Chahine, Samuel Frank, Klaus Seppi, Holly Shill, Daniela Berg, Zoltan Mari, Nicola Pavese, Alberto Espay, Johnna Devoto, Dominic Rowe, Melanie Brandabur, Roy Alcalay, Eduardo Tolosa, Michele York, Laura Leary, Cheryl Riordan, Linda Rees, Alicia Portillo, Art Lenahan, Karen Williams, Stephanie Guthrie, Ashlee Rawlins, Sherry Harlan, Christine Hunter, Baochan Tran, Cathi Ann Thomas, Raymond James, Fabienne Sprenger, Diana Willeke, Sanja Obradov, Jennifer Mule, Katharina Gauss, Deborah Fontaine, Bina Shah, Madelaine Ranola, John R. Sims, Parkinson's Progression Markers Initiative

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

229 Citations (Scopus)

Abstract

This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). Conclusions: Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS.

Original language	English
Pages (from-to)	919-927
Number of pages	9
Journal	Movement disorders : official journal of the Movement Disorder Society
Volume	30
Issue number	7
DOIs	https://doi.org/10.1002/mds.26170
Publication status	Published - 1 Jun 2015

Access to Document

10.1002/mds.26170

Cite this

Weintraub, D., Simuni, T., Caspell-Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., Eberling, J., Espay, A. J., Foster, E. D., Leverenz, J. B., Litvan, I., Richard, I., Troyer, M. D., Hawkins, K. A., Marek, K., ... Parkinson's Progression Markers Initiative (2015). Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 30(7), 919-927. https://doi.org/10.1002/mds.26170

@article{c147b9b4b97141d09bde93096b05a649,

title = "Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease",

abstract = "This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). Conclusions: Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS.",

author = "Daniel Weintraub and Tanya Simuni and Chelsea Caspell-Garcia and Christopher Coffey and Shirley Lasch and Andrew Siderowf and Dag Aarsland and Paolo Barone and David Burn and Chahine, {Lama M.} and Jamie Eberling and Espay, {Alberto J.} and Foster, {Eric D.} and Leverenz, {James B.} and Irene Litvan and Irene Richard and Troyer, {Matthew D.} and Hawkins, {Keith A.} and Kenneth Marek and Danna Jennings and Caroline Tanner and Karl Kieburtz and Werner Poewe and Brit Mollenhauer and Tatiana Foroud and Douglas Galasko and Todd Sherer and Sohini Chowdhury and Mark Frasier and Catherine Kopil and Vanessa Arnedo and Alice Rudolph and John Seibyl and Susan Mendick and Norbert Schuff and Chelsea Caspell and Liz Uribe and Eric Foster and Katherine Gloer and Jon Yankey and Arthur Toga and Dorit Berlin and Paola Casalin and Giulia Malferrari and John Trojanowski and Les Shaw and David Russell and Stewart Factor and Penelope Hogarth and David Standaert and Robert Hauser and Joseph Jankovic and Matthew Stern and Lama Chahine and Samuel Frank and Klaus Seppi and Holly Shill and Daniela Berg and Zoltan Mari and Nicola Pavese and Alberto Espay and Johnna Devoto and Dominic Rowe and Melanie Brandabur and Roy Alcalay and Eduardo Tolosa and Michele York and Laura Leary and Cheryl Riordan and Linda Rees and Alicia Portillo and Art Lenahan and Karen Williams and Stephanie Guthrie and Ashlee Rawlins and Sherry Harlan and Christine Hunter and Baochan Tran and Thomas, {Cathi Ann} and Raymond James and Fabienne Sprenger and Diana Willeke and Sanja Obradov and Jennifer Mule and Katharina Gauss and Deborah Fontaine and Bina Shah and Madelaine Ranola and Sims, {John R.} and {Parkinson's Progression Markers Initiative}",

year = "2015",

month = jun,

day = "1",

doi = "10.1002/mds.26170",

language = "English",

volume = "30",

pages = "919--927",

journal = "Movement disorders : official journal of the Movement Disorder Society",

issn = "0885-3185",

publisher = "Lippincott Williams & Wilkins",

number = "7",

}

Weintraub, D, Simuni, T, Caspell-Garcia, C, Coffey, C, Lasch, S, Siderowf, A, Aarsland, D, Barone, P, Burn, D, Chahine, LM, Eberling, J, Espay, AJ, Foster, ED, Leverenz, JB, Litvan, I, Richard, I, Troyer, MD, Hawkins, KA, Marek, K, Jennings, D, Tanner, C, Kieburtz, K, Poewe, W, Mollenhauer, B, Foroud, T, Galasko, D, Sherer, T, Chowdhury, S, Frasier, M, Kopil, C, Arnedo, V, Rudolph, A, Seibyl, J, Mendick, S, Schuff, N, Caspell, C, Uribe, L, Foster, E, Gloer, K, Yankey, J, Toga, A, Berlin, D, Casalin, P, Malferrari, G, Trojanowski, J, Shaw, L, Russell, D, Factor, S, Hogarth, P, Standaert, D, Hauser, R, Jankovic, J, Stern, M, Chahine, L, Frank, S, Seppi, K, Shill, H, Berg, D, Mari, Z, Pavese, N, Espay, A, Devoto, J, Rowe, D, Brandabur, M, Alcalay, R, Tolosa, E, York, M, Leary, L, Riordan, C, Rees, L, Portillo, A, Lenahan, A, Williams, K, Guthrie, S, Rawlins, A, Harlan, S, Hunter, C, Tran, B, Thomas, CA, James, R, Sprenger, F, Willeke, D, Obradov, S, Mule, J, Gauss, K, Fontaine, D, Shah, B, Ranola, M, Sims, JR & Parkinson's Progression Markers Initiative 2015, 'Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease', Movement disorders : official journal of the Movement Disorder Society, vol. 30, no. 7, pp. 919-927. https://doi.org/10.1002/mds.26170

TY - JOUR

T1 - Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

AU - Weintraub, Daniel

AU - Simuni, Tanya

AU - Caspell-Garcia, Chelsea

AU - Coffey, Christopher

AU - Lasch, Shirley

AU - Siderowf, Andrew

AU - Aarsland, Dag

AU - Barone, Paolo

AU - Burn, David

AU - Chahine, Lama M.

AU - Eberling, Jamie

AU - Espay, Alberto J.

AU - Foster, Eric D.

AU - Leverenz, James B.

AU - Litvan, Irene

AU - Richard, Irene

AU - Troyer, Matthew D.

AU - Hawkins, Keith A.

AU - Marek, Kenneth

AU - Jennings, Danna

AU - Tanner, Caroline

AU - Kieburtz, Karl

AU - Poewe, Werner

AU - Mollenhauer, Brit

AU - Foroud, Tatiana

AU - Galasko, Douglas

AU - Sherer, Todd

AU - Chowdhury, Sohini

AU - Frasier, Mark

AU - Kopil, Catherine

AU - Arnedo, Vanessa

AU - Rudolph, Alice

AU - Seibyl, John

AU - Mendick, Susan

AU - Schuff, Norbert

AU - Caspell, Chelsea

AU - Uribe, Liz

AU - Foster, Eric

AU - Gloer, Katherine

AU - Yankey, Jon

AU - Toga, Arthur

AU - Berlin, Dorit

AU - Casalin, Paola

AU - Malferrari, Giulia

AU - Trojanowski, John

AU - Shaw, Les

AU - Russell, David

AU - Factor, Stewart

AU - Hogarth, Penelope

AU - Standaert, David

AU - Hauser, Robert

AU - Jankovic, Joseph

AU - Stern, Matthew

AU - Chahine, Lama

AU - Frank, Samuel

AU - Seppi, Klaus

AU - Shill, Holly

AU - Berg, Daniela

AU - Mari, Zoltan

AU - Pavese, Nicola

AU - Espay, Alberto

AU - Devoto, Johnna

AU - Rowe, Dominic

AU - Brandabur, Melanie

AU - Alcalay, Roy

AU - Tolosa, Eduardo

AU - York, Michele

AU - Leary, Laura

AU - Riordan, Cheryl

AU - Rees, Linda

AU - Portillo, Alicia

AU - Lenahan, Art

AU - Williams, Karen

AU - Guthrie, Stephanie

AU - Rawlins, Ashlee

AU - Harlan, Sherry

AU - Hunter, Christine

AU - Tran, Baochan

AU - Thomas, Cathi Ann

AU - James, Raymond

AU - Sprenger, Fabienne

AU - Willeke, Diana

AU - Obradov, Sanja

AU - Mule, Jennifer

AU - Gauss, Katharina

AU - Fontaine, Deborah

AU - Shah, Bina

AU - Ranola, Madelaine

AU - Sims, John R.

AU - Parkinson's Progression Markers Initiative

PY - 2015/6/1

Y1 - 2015/6/1

N2 - This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). Conclusions: Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS.

AB - This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background: Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. Methods: Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. Results: Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). Conclusions: Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS.

UR - http://www.scopus.com/inward/record.url?scp=84931955787&partnerID=8YFLogxK

U2 - 10.1002/mds.26170

DO - 10.1002/mds.26170

M3 - Article

C2 - 25737166

AN - SCOPUS:84931955787

SN - 0885-3185

VL - 30

SP - 919

EP - 927

JO - Movement disorders : official journal of the Movement Disorder Society

JF - Movement disorders : official journal of the Movement Disorder Society

IS - 7

ER -

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this